生物学标志物在糖尿病肾病早期诊断中的研究进展

Abstract
Figure/Table
References (27)
Related Citation (15)

Download: PDF (0 KB) HTML (38 KB)
Export: BibTeX | EndNote (RIS)

Abstract Diabetic nephropathy (DN), defined as urinary albumin excretion rate (UAER) >300 mg/24 h and declining renal function in a patient with known diabetes mellitus (DM) in the absence of urinary tract infection or any other renal diseases.DN is a common microvascular complication of DM.Searching for biomarkers with high sensitivity and specificity is helpful for early diagnosis and treatment of DN to improve the prognosis of patients.In order to provide researchers with the current research status of DN, this paper will summarize and discuss the research progress of biomarkers in the early diagnosis of DN based on glomerular and tubular injury, oxidative stress, inflammation and proteomics, hoping that biomarkers can be used in clinical work as soon as possible.

Key words： Diabetic nephropathy Biomarker Microalbuminuria Research progress

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	JI Chao
	SONG Yu-ling
	LIU Chang-mei

Cite this article:

JI Chao,SONG Yu-ling,LIU Chang-mei. Research progress of biomarkers in early diagnosis of diabetic nephropathy[J]. 中国当代医药, 2021, 28(10): 36-39.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2021/V28/I10/36

[1]	Currie G，McKay G，Delles C.Biomarkers in diabetic nephropathy：Present and future[J].World J Diabetes，2014，5（6）：763-776.
[2]	Chatzikyrkou C，Menne J，Izzo J，et al.Predictors for the development of microalbuminuria and interaction with renal function[J].J Hypertens，2017，35（12）：2501-2509.
[3]	Jansson FJ，Forsblom C，Harjutsalo V，et al.Regression of albuminuria and its association with incident cardiovascular outcomes and mortality in type 1 diabetes：the FinnDiane Study[J].Diabetologia，2018，61（5）：1203-1211.
[4]	Gao P，Xu B，Song P，et al.The Kidney Specific Protein myo-Inositol Oxygenase，a Potential Biomarker for Diabetic Nephropathy[J].Kidney Blood Press Res，2018，43（6）：1772-1785.
[5]	Arceo ES，Dizon GA，Tiongco REG.Serum cystatin C as an early marker of nephropathy among type 2 diabetics：A meta-analysis[J].Diabetes Metab Syndr，2019，13（6）：3093-3097.
[6]	Ghanbari Z，Housaindokht M R，Bozorgmehr M R，et al.The effect of glycosylation on the transferrin structure：A molecular dynamic simulation analysis[J].J Theor Biol，2016，404：73-81.
[7]	Narita T，Hosoba M，Kakei M，et al.Increased urinary excretions of immunoglobulin g，ceruloplasmin，and transferrin predict development of microalbuminuria in patients with type 2 diabetes[J].Diabetes Care，2006，29（1）：142-144.
[8]	Araki S，Haneda M，Koya D，et al.Association between urinary type Ⅳcollagen level and deterioration of renal function in type 2 diabetic patients without overt proteinuria[J].Diabetes Care，2010，33（8）：1805-1810.
[9]	Mahendran KB，Bhaskar MV，Santha K，et al.Plasma and Urinary Type ⅣCollagen Levels for Early Detection of Nephropathy in Type 2 Diabetes Mellitus Patients[J].Int J Health Sci（Qassim），2016，10（4）：492-498.
[15]	Moresco RN，Bochi GV，Stein CS，et al.Urinary kidney injury molecule-1 in renal disease[J].Clinica Chimica Acta，2018，487：15-21.
[10]	Zeni L，Norden AGW，Cancarini G，et al.A more tubulocentric view of diabetic kidney disease[J].J Nephrol，2017，30（6）：701-717.
[11]	Kim SY，Jeong TD，Lee W，et al.Plasma Neutrophil Gelatinase-Associated Lipocalin as a Marker of Tubular Damage in Diabetic Nephropathy[J].Ann Lab Med，2018，38（6）：524-529.
[12]	Abbasi F，Moosaie F，Khaloo P，et al.Neutrophil Gelatinase-Associated Lipocalin and Retinol-Binding Protein-4 as Biomarkers for Diabetic Kidney Disease[J].Kidney Blood Press Res，2020，45（2）：222-232.
[13]	Assal HS，Tawfeek S，Rasheed EA，et al.Serum cystatin C and tubular urinary enzymes as biomarkers of renal dysfunction in type 2 diabetes mellitus[J].Clin Med Insights Endocrinol Diabetes，2013，6：7-13.
[14]	Katayama M，Ohata K，Miyazaki T，et al.Renal expression and urinary excretion of liver-type fatty acid-binding protein in cats with renal disease[J].J Vet Intern Med，2020，34（2）：761-769.
[16]	Nielsen SE，Sugaya T，Tarnow L，et al.Tubular and glomerular injury in diabetes and the impact of ACE inhibitions[J].Diabetes Care，2009，32（9）：1684-1688.
[17]	Chou KM，Lee CC，Chen CH，et al.Clinical value of NGAL，L-FABP and albuminuria in predicting GFR decline in type 2 diabetes mellitus patients[J].PLoS One，2018，8（1）：e54863.
[18]	Li A，Yi B，Liu Y，et al.Urinary NGAL and RBP Are Biomarkers of Normoalbuminuric Renal Insufficiency in Type 2 Diabetes Mellitus[J].J Immunol Res，2019，2019：5 063 089.
[19]	Futrakul N，Futrakul P.Biomarker for early renal microvascular and diabetic kidney diseases[J].Ren Fail，2017，39（1）：505-511.
[20]	Lu Y，Chen L，Zhao B，et al.Urine AQP5 is a potential novel biomarker of diabetic nephropathy[J].J Diabetes Complications，2016，30（5）：819-825.
[21]	Jha JC，Banal C，Chow BS，et al.Diabetes and Kidney Disease：Role of Oxidative Stress[J].Antioxid Redox Signal，2016，25（12）：657-684.
[22]	Broedbaek K，Weimann A，Stovgaard ES，et al.Urinary 8-oxo-7，8-dihydro-2′-deoxyguanosine as a biomarker in type 2 diabetes[J].Free Radic Biol Med，2011，51（8）：1473-1479.
[23]	Kern EF，Erhard P，Sun W，et al.Early urinary markers of diabetic kidney disease：a nested case-control study from the Diabetes Control and Complications Trial（DCCT）[J].Am J Kidney Dis，2010，55（5）：824-834.
[24]	Schlatzer D，Maahs DM，Chance MR，et al.Novel urinary protein biomarkers predicting the development of microalbuminuria and renal function decline in type 1 diabetes[J].Diabetes Care，2012，35（3）：549-555.
[25]	Jiang B，Guo L，Li BY，et al.Resveratrol attenuates early diabetic nephropathy by down-regulating glutathione stransferases Mu in diabetic rats[J].J Med Food，2013，16（6）：481-486.
[26]	Noce A，Fabrini R，Dessì M，et al.Erythrocyte glutathione transferase activity：a possible early biomarker for blood toxicity in uremic diabetic patients[J].Acta Diabetol，2014，51（2）：219-224.
[27]	Wang Y，Zhou Q，Zhang L，et al.Urine Haptoglobin/Creatinine Ratio Correlates with Tubular Injury Biomarkers and Severity of Albuminuria in Type 2 Diabetes Patients[J].Horm Metab Res，2019，51（9）：595-601.